Incyte (INCY) Long-Term Investments (2014 - 2026)
Incyte posted quarterly Long-Term Investments of $54.6 million for Q1 2026, up 212.56% year-on-year from $17.5 million in Q1 2025, and up 13.73% on a QoQ basis from $48.0 million in Q4 2025.
Incyte (INCY) has 13 years of Long-Term Investments data on file, last reported at $54.6 million in Q1 2026.
- For the quarter ending Q1 2026, Long-Term Investments rose 212.56% year-over-year to $54.6 million; the trailing twelve-month figure through Mar 2026 stood at $54.6 million (up 212.56% YoY), and the FY2025 full-year result was $48.0 million, up 155.08% from the prior year.
- Long-Term Investments for Q1 2026 stood at $54.6 million, up from $48.0 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $287.7 million in Q1 2024 and bottomed at $1.6 million in Q3 2022.
- The 5-year median for Long-Term Investments is $48.0 million (2025), against an average of $85.0 million.
- The widest annual swing landed in 2022, when Long-Term Investments sank 99.17%; it then jumped 9497.94% in 2023.
- A 5-year view of Long-Term Investments shows it stood at $133.7 million in 2022, then soared by 40.43% to $187.7 million in 2023, then sank by 89.98% to $18.8 million in 2024, then soared by 155.08% to $48.0 million in 2025, then gained by 13.73% to $54.6 million in 2026.
- The last three Long-Term Investments figures came in at $54.6 million (Q1 2026), $48.0 million (Q4 2025), and $21.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn | 54.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 54.58 Mn |
| Dec 31, 2025 | 47.99 Mn |
| Sep 30, 2025 | 21.87 Mn |
| Jun 30, 2025 | 13.31 Mn |
| Mar 31, 2025 | 17.46 Mn |
| Dec 31, 2024 | 18.81 Mn |
| Sep 30, 2024 | 27.57 Mn |
| Jun 30, 2024 | 29.67 Mn |
| Mar 31, 2024 | 287.66 Mn |
| Dec 31, 2023 | 187.72 Mn |
| Sep 30, 2023 | 153.66 Mn |
| Jun 30, 2023 | 170.32 Mn |
| Mar 31, 2023 | 128.31 Mn |
| Dec 31, 2022 | 133.68 Mn |
| Sep 30, 2022 | 1.60 Mn |
| Jun 30, 2022 | 149.78 Mn |
| Mar 31, 2022 | 1.70 Mn |
| Dec 31, 2021 | 221.27 Mn |
| Sep 30, 2021 | 192.10 Mn |
| Jun 30, 2021 | 220.69 Mn |
| Mar 31, 2021 | 1.64 Mn |
| Dec 31, 2020 | 1.76 Mn |
| Sep 30, 2020 | 222.81 Mn |
| Jun 30, 2020 | 248.73 Mn |
| Mar 31, 2020 | 2.55 Mn |
| Dec 31, 2019 | 1.02 Mn |
| Jun 30, 2019 | 115.56 Mn |
| Mar 31, 2019 | 995,000.00 |
| Dec 31, 2018 | 1.40 Mn |
| Sep 30, 2018 | 1.01 Mn |
| Jun 30, 2018 | 131.33 Mn |
| Mar 31, 2018 | 165.97 Mn |
| Dec 31, 2017 | 11.60 Mn |
| Sep 30, 2017 | 11.60 Mn |
| Jun 30, 2017 | 11.60 Mn |
| Mar 31, 2017 | 39.50 Mn |
| Dec 31, 2016 | 886,000.00 |
| Sep 30, 2016 | 55.75 Mn |
| Jun 30, 2016 | 31.44 Mn |
| Mar 31, 2016 | 32.30 Mn |
| Dec 31, 2015 | 39.80 Mn |
| Sep 30, 2015 | 18.11 Mn |
| Jun 30, 2015 | 67.00 Mn |
| Mar 31, 2015 | 39.83 Mn |
| Dec 31, 2014 | 14.00 Mn |